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Plasminogen activator inhibitor 1 (PAI-1) is the main inhibitor of the fi brinolytic system 
and binds irreversibly to tissue-type plasminogen activator (t-PA), and thereby inhibits 
the protective action of t-PA against thrombus formation. Elevated levels of plasma PAI-1 
is observed in subjects with type 2 diabetes (T2D) and the metabolic syndrome (MetS), 
which is a combination of metabolic features including obesity. PAI-1 has become recog-
nized as a central molecule linking the MetS and thrombotic vascular events. However, 
the origin of plasma PAI-1 is not fully established in these conditions. The aim of this 
thesis was to investigate the role of platelet PAI-1 and source of plasma PAI-1 in T2D, 
obesity and healthy subjects. 
Our group has previously shown that platelets can de novo synthesize PAI-1 and the 
amount synthesized in vitro in 24 hours is 35-fold higher than required to maintain nor-
mal plasma levels. Therefore we wanted to investigate if platelets are the cellular origin 
of plasma PAI-1. Tissue-specifi c glycosylation patterns on PAI-1 from different tissues 
were determined. The results indicate that platelets are the source of plasma PAI-1, since 
no glycans were detected on PAI-1 isolated from plasma or platelets from healthy lean 
subjects. PAI-1 isolated from the other tissues expressed heterogeneous glycosylation 
patterns. 
In obese subjects plasma PAI-1 had a glycan composition similar to that of adipose tissue 
suggesting that obese subjects, with elevated PAI-1 levels, may have an additional con-
tribution from adipose tissue. Since glycosylated PAI-1, in comparison to unglycosylated 
forms, exhibit a lower inactivation rate and a stronger inhibitory effect, we also studied 
the level of glycosylated plasma PAI-1 in obesity. This was increased in obese subjects by 
54% compared to lean subjects and a weak but signifi cant correlation between the level 
of glycosylation and BMI was observed. These results suggest that an elevated level of 
glycosylated plasma PAI-1 is an important contributor to the increased risk of cardiovas-
cular events associated with increased plasma PAI-1 levels in obese subjects.
Diabetic platelets are known to be hyper-reactive and larger in size; however, whether 
these features affect their contribution to the elevated levels of plasma PAI-1 in T2D is 
unknown. To elucidate the role of platelet PAI-1 in T2D, we characterized the PAI-1 
antigen content and the mRNA expression in platelets from T2D subjects compared to 
both obese and lean control subjects. In order to analyze the mRNA content in platelets, 
reference genes to normalize for qPCR were identifi ed and YWHAE was the most stable 
transcript in platelets. Furthermore, there was no signifi cant difference in PAI-1 mRNA 
expression or PAI-1 antigen in platelets comparing the three groups, but an elevated 
level of plasma PAI-1 was seen in both T2D and obese control subject, indicating an un-
effected role of platelets.
In conclusion, in balanced physiological conditions, platelets may be the major source of 
plasma PAI-1, however, the platelet contribution seems less important for the increased 
plasma levels and hence the risk of cardiovascular events in MetS and T2D. 
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